Navigation Links
KV Pharmaceutical Receives Letter From NYSE Regarding Delayed Filing of Its 2009 Annual Report on Form 10-K
Date:6/22/2009

spects of the Company. Such statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could" and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, including without limitation, product development, product launches, regulatory approvals, market position, acquisitions, sale of assets, revenues, expenditures, resumption of manufacturing and distribution of products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.

All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, political and technological factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.

Such factors include (but are not limited to) the following: (1) the ability to continue as a going concern; (2) changes in the current and future business environment, including interest rates and capital and consumer spending; (3) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (4) the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals; (5) acceptance and demand for new pharmaceutical products; (6) the introduction and impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (7) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (8) reliance on ke
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... women who received the Human Papillomavirus Vaccination (HPV) ... of abnormal Pap test results than those who ... journal Sexually Transmitted Diseases . , ... and School of Medicine conducted a cross-sectional study ... routine cervical cytology testing. HPV status and demographic ...
(Date:7/24/2014)... According to market research report "3D Mapping Market: ... Analysis - 2018", the 3D mapping and 3D ... by 2018 at a CAGR of 47.9% by ... and 30 figures spread through 222 pages and ... Business Models, Technology Roadmap, Forecasts and Analysis - ...
(Date:7/24/2014)... York (PRWEB) July 24, 2014 ... ( http://www.drugbot.com/testosterone/lawsuit/ ) against the manufacturer of Delatestryl, ... risks associated with the low testosterone injection, Bernstein ... was filed in the Ontario Superior Court of ... use of low testosterone therapy is associated with ...
(Date:7/24/2014)... 24, 2014 (HealthDay News) -- Giving low-income families vouchers ... increase their consumption of these healthy foods, according to ... fewer fruits and vegetables. In addition to not having ... issue. Farmers, market vouchers could help address both of ... healthy food options, farmers, market incentives may be able ...
(Date:7/24/2014)... new formulation of a powerful narcotic painkiller that discourages ... been approved by the U.S. Food and Drug Administration. ... the pill is a combination of the narcotic oxycodone ... of oxycodone. The naloxone is only activated when the ... the FDA. While Targiniq has only been approved ...
Breaking Medicine News(10 mins):Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuit News: Canadian Plaintiffs File Class Action Lawsuit Against Manufacturer of Delatestryl Testosterone Injection, Bernstein Liebhard LLP Reports 3Health News:Farmers' Market Vouchers May Help Poorer Families Eat Healthier 2Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2
... GenPrime, Inc. a leading,provider of rapid microbial analysis ... Contamination Test for Platelets(TM). The,test is a rapid ... and,anaerobic bacteria commonly found in contaminated platelets. The ... pre-market notification with the Food,and Drug Administration (FDA). ...
... ago, deconstructing and analyzing DNA codes took scientists several years ... floor of a building. Now, a genetic sequencer the ... a couple of days. , Thanks to a ... of Houstons Institute for Molecular Design (IMD), researchers will be ...
... example of the Bush Administration promoting, politics over a sound health ... oversight of the federal family planning program and the health of ... ... National Abortion,Federation (NAF) denounces the appointment of Dr. Susan Orr as ...
... Next Big Challenge, WASHINGTON, Oct. 17 Is ... drugs,and devices to physicians and the public?, That,s ... and debate at a,landmark Colloquium, Communicating Risk/Safety Information: How ... Drug Law Institute (FDLI),Dec. 6, 2007, in Washington, D.C., ...
... Oct. 17 40|86 Strategic Income,Fund (NYSE: CFD ... 9, 2007 to holders of record at the close ... Fund is a closed-end investment management,company. The Fund,s primary ... in the Fund,s prospectus, the Fund intends to,distribute substantially ...
... Care, Inc. (NYSE:,HCR) announced that at its special ... merger agreement providing for the,merger of Manor Care, ... 99 percent of the shares present and voting ... number of shares voting to approve,the merger agreement ...
Cached Medicine News:Health News:GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets 2Health News:Half-million-dollar DNA sequencer to boost genetic science research at UH 2Health News:National Abortion Federation Denounces the Appointment of Dr. Orr to Oversee Federal Family Planning Funds 2Health News:Food and Drug Law Institute Sponsors Colloquium on Communicating Risk/Safety Drug Information 2
(Date:7/24/2014)... -- Delivery of the Report will take 2-3 ... Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... on Global and Chinese Hemodialysis Machine industry. The ... Machine including its classification, application and manufacturing technology. ... manufacturers of Hemodialysis Machine listing their product specification, ...
(Date:7/24/2014)... 24, 2014 Cancer patients in the west of ... cancer treatment closer to home when a new radiotherapy center ... Medical Systems (NYSE: VAR ) has been selected ... in June for four TrueBeam™ medical linear accelerators. ... and efficient radiotherapy and radiosurgery treatments, will replace older treatment ...
(Date:7/24/2014)...  Blueprint Medicines (Blueprint), a leader in discovering highly ... announced the appointment of Jeffrey Albers as ... Algeta ASA, where he served on the executive management ... Bayer. Mr. Albers succeeds Alexis Borisy , co-founder ... Rock Ventures, who will remain an active member of ...
Breaking Medicine Technology:Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3Blueprint Medicines Appoints Jeffrey Albers as Chief Executive Officer 2
... Nov. 14, 2011 Tengion, Inc. (Nasdaq: ... of a restructuring plan, and reported its financial results ... restructuring plan is designed to fund the Company,s lead ... the Company,s anticipated cash utilization.  As a result of ...
... Texas, Nov. 14, 2011 Novation commends the IMS ... raising awareness of the drug shortage crisis facing America,s ... Look at Products, Suppliers and Volume Volatility."   ... 2011 Executive Order, is helping bring much-needed attention to ...
Cached Medicine Technology:Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 2Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 3Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 4Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 5Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 6Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 7Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 8Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 9Tengion Provides Business Update and Reports Third Quarter 2011 Financial Results 10Novation Applauds the IMS Institute for Healthcare Informatics for Calling Attention to the Drug Shortage Crisis Facing American Hospitals 2Novation Applauds the IMS Institute for Healthcare Informatics for Calling Attention to the Drug Shortage Crisis Facing American Hospitals 3
The XT-1800i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The XT-2000i is a compact, high performance, automated hematology analyzer that provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test re...
The XE-2100L automated hematology analyzer features new hematology parameters as NRBC, IRF, and HPC that offer valuable and accurate clinical information....
The XE-2100 automated hematology analyzer features new hematology parameters as NRBC, IRF, and HPC that offer valuable and accurate clinical information....
Medicine Products: